Literature DB >> 24397483

Discordant clinical presentations of preeclampsia and intrauterine fetal growth restriction with similar pro- and anti-angiogenic profiles.

Thushari I Alahakoon1, Weiyi Zhang, Brian J Trudinger, Vincent W Lee.   

Abstract

OBJECTIVE: To evaluate the plasma levels of angiogenic factors in preeclampsia (PE) and intrauterine fetal growth restriction (IUGR) and their potential as biomarkers to distinguish normal from pathologic pregnancies.
METHODS: Case control study included singleton pregnancies in four categories: (i) normal (n = 29), (ii) PE (n = 15), (iii) PE and IUGR (n = 16) and (iv) IUGR (n = 24). The classification of IUGR included umbilical artery Doppler resistance. Maternal plasma placental growth factor (PlGF), soluble fms-like tyrosine kinase-1 (sFlt-1), soluble kinase domain receptor (sKDR) and soluble endoglin (sEng) as well as fetal umbilical artery sFlt-1 levels were determined. Each individual marker and their ratios were assessed for their potential to distinguish normal pregnancy from pregnancies affected by PE and/or IUGR.
RESULTS: We found (i) elevated plasma sFlt-1, sEng and reduced PlGF, sKDR in PE and IUGR; (ii) similar angiogenic profiles in PE and IUGR and (iii) sEng and sFlt-1*sEng/PlGF performed best as biomarkers in identifying pathologic pregnancies.
CONCLUSIONS: PE and IUGR have similar angiogenic profiles, suggesting that angiogenic marker profiles lack specificity in identifying PE and that other factors are required for the development of PE instead of IUGR. sEng should be included in a biomarker profile for predicting PE or IUGR.

Entities:  

Keywords:  Angiogenic factors; fetal growth restriction; preeclampsia

Mesh:

Substances:

Year:  2014        PMID: 24397483     DOI: 10.3109/14767058.2014.880882

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  13 in total

1.  Placental Complications and Bronchopulmonary Dysplasia: EPIPAGE-2 Cohort Study.

Authors:  Héloïse Torchin; Pierre-Yves Ancel; François Goffinet; Jean-Michel Hascoët; Patrick Truffert; Diep Tran; Cécile Lebeaux; Pierre-Henri Jarreau
Journal:  Pediatrics       Date:  2016-02-18       Impact factor: 7.124

2.  Pravastatin to prevent recurrent fetal death in massive perivillous fibrin deposition of the placenta (MPFD).

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Steven J Korzeniewski; Piya Chaemsaithong; Edgar Hernandez-Andrade; James H Segars; Alan H DeCherney; M Cathleen McCoy; Chong Jai Kim; Lami Yeo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2015-04-20

3.  Placental growth factor influences maternal cardiovascular adaptation to pregnancy in mice.

Authors:  Kristiina L Aasa; Bruno Zavan; Rayana L Luna; Philip G Wong; Nicole M Ventura; M Yat Tse; Peter Carmeliet; Michael A Adams; Stephen C Pang; B Anne Croy
Journal:  Biol Reprod       Date:  2014-12-23       Impact factor: 4.285

4.  Maternal plasma-soluble ST2 concentrations are elevated prior to the development of early and late onset preeclampsia - a longitudinal study.

Authors:  Roberto Romero; Piya Chaemsaithong; Adi L Tarca; Steven J Korzeniewski; Eli Maymon; Percy Pacora; Bogdan Panaitescu; Noppadol Chaiyasit; Zhong Dong; Offer Erez; Sonia S Hassan; Tinnakorn Chaiworapongsa
Journal:  J Matern Fetal Neonatal Med       Date:  2017-03-01

5.  The use of angiogenic biomarkers in maternal blood to identify which SGA fetuses will require a preterm delivery and mothers who will develop pre-eclampsia.

Authors:  Tinnakorn Chaiworapongsa; Roberto Romero; Amy E Whitten; Steven J Korzeniewski; Piya Chaemsaithong; Edgar Hernandez-Andrade; Lami Yeo; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2016

6.  Biochemical tests of placental function versus ultrasound assessment of fetal size for stillbirth and small-for-gestational-age infants.

Authors:  Alexander Ep Heazell; Dexter Jl Hayes; Melissa Whitworth; Yemisi Takwoingi; Susan E Bayliss; Clare Davenport
Journal:  Cochrane Database Syst Rev       Date:  2019-05-14

Review 7.  Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice.

Authors:  H Stepan; I Herraiz; D Schlembach; S Verlohren; S Brennecke; F Chantraine; E Klein; O Lapaire; E Llurba; A Ramoni; M Vatish; D Wertaschnigg; A Galindo
Journal:  Ultrasound Obstet Gynecol       Date:  2015-03       Impact factor: 7.299

8.  A Common Profile of Disordered Angiogenic Factor Production and the Exacerbation of Inflammation in Early Preeclampsia, Late Preeclampsia, and Intrauterine Growth Restriction.

Authors:  Sebastian Kwiatkowski; Barbara Dołęgowska; Ewa Kwiatkowska; Rafał Rzepka; Andrzej Torbè; Magdalena Bednarek-Jędrzejek
Journal:  PLoS One       Date:  2016-10-19       Impact factor: 3.240

Review 9.  Placental Growth Factor as a Prognostic Tool in Women With Hypertensive Disorders of Pregnancy: A Systematic Review.

Authors:  U Vivian Ukah; Jennifer A Hutcheon; Beth Payne; Matthew D Haslam; Manu Vatish; J Mark Ansermino; Helen Brown; Laura A Magee; Peter von Dadelszen
Journal:  Hypertension       Date:  2017-10-30       Impact factor: 10.190

10.  Bronchopulmonary dysplasia in neonates born to mothers with preeclampsia: Impact of small for gestational age.

Authors:  Pauline Dravet-Gounot; Héloïse Torchin; François Goffinet; Marie-Stéphanie Aubelle; Mayass El Ayoubi; Claire Lefevre; Pierre-Henri Jarreau; Elodie Zana-Taïeb
Journal:  PLoS One       Date:  2018-09-24       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.